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Background
Specific antibodies to cow’s milk (CM) may have prog-
nostic value in CM allergy. We hypothesized that they
may also help in predicting the clinical outcome of oral
immunotherapy (OIT) prior to treatment, and that
changes in specific antibody levels during the therapy
may reflect its efficacy.
Methods
We investigated 40 children aged 6-17 year with cow’s
milk allergy who either successfully completed OIT
(n=32) or discontinued the therapy due to side effects
(n=8). We analyzed in sera drawn before and after OIT
specific IgA, IgG, IgG1 and IgG4 to CM, casein, beta-
lactoglobulin and ovalbumin with enzyme linked immu-
nosorbent assay, and IgE to CM and hen’s egg white
with enzymatic fluoroimmunoassay (Pharmacia CAP
system).
Results
Specific IgA, IgG, IgG1 and IgG4 to CM and casein, and
CM specific IgE prior to OIT were higher in children
who eventually discontinued the therapy compared with
children who achieved desensitization (p<0.05). Side
effects in the entire population were associated with
high IgG, IgG1, but low IgG4 levels to ovalbumin
(p<0.05). Specific IgA, IgG, IgG1 and IgG4 to CM pro-
teins significantly increased and IgE to CM decreased
from the start to end of OIT in children who achieved
desensitization (p<0.01), whereas in those who inter-
rupted OIT only IgG, IgG1 and IgG4 to CM increased
significantly (p<0.03).
Conclusions
High specific IgE, IgA and class IgG antibodies to CM
proteins appear to predict failure to achieve desensitization
in CM OIT. Specific IgA and class IgG antibodies to
CM increase and CM IgE decreases during desensitization.
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